Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals.

ABSTRACT: Although aspirin has been considered a promising agent for prevention of colorectal cancer, recent data suggest a lack of benefit among older individuals. Whether some individuals with higher risk of colorectal cancer may benefit from aspirin remains unknown. We used a 95-variant colorectal cancer polygenic risk score (PRS) to explore the association between genetic susceptibility to colorectal cancer and aspirin use in a prospective study of 12,609 individuals of European descent ages ≥70 years, enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) double-blinded, placebo-controlled randomized trial (randomized controlled trial; RCT). Cox proportional hazards models were used to assess the association of aspirin use on colorectal cancer, as well as the interaction between the

SUBMITTER: Bakshi A 

PROVIDER: S-EPMC9256779 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature